InsufficientPreprint
This study investigates GHK-Cu — a copper-based amino acid complex — as an interfacial modifier inserted between the perovskite layer and the Spiro-OMeTAD hole-transport layer (HTL) in perovskite solar cells (PSCs). The researchers found that GHK-Cu's molecular flexibility and polarity-responsive coordination chemistry allowed it to expose multiple functional groups (─C=O, ─COOH, and ─NH₂) that interact with undercoordinated ionic defects via coordination bonds and hydrogen bonding. These interactions drove GHK-Cu to self-assemble into a mesoporous architecture at the interface, which then reorganized Spiro-OMeTAD into a hybrid mesoporous@Spiro-OMeTAD HTL. The authors report that this structure creates continuous hole-transport channels, reduces thermomechanical stress, and suppresses ion migration. Devices incorporating this interlayer reportedly achieved a power conversion efficiency (PCE) of 26.72%, with a certified PCE of 26.34%, and retained 95% of initial efficiency after 1,600 hours of maximum power point tracking at 85°C. Limitations include the preprint status of the work, meaning it has not yet undergone formal peer review, and the results reflect a specific device architecture that may not generalize broadly.
Unknown journal · Jun 2026DOI ↗ InsufficientPreprint
This study analyzed a large, publicly available independent testing dataset of 6,441 samples spanning fourteen peptide compounds sold through largely unregulated gray market channels directly to consumers. Compounds examined included BPC-157, semaglutide, tirzepatide, PT-141, TB-500, thymosin beta-4, and others marketed for purposes such as injury recovery, muscle growth, fat loss, and athletic performance. Researchers applied two quality acceptance frameworks — one approximating standards for 503A compounded medications and a stricter model reflecting FDA-approved drug production standards — to assess purity, measured abundance, and endotoxin burden. The study found that between 41.6% and 71.1% of samples failed to meet basic quality criteria depending on the framework applied, and measurable endotoxin contamination was detected in 15% of samples. Gray market peptides were consistently cheaper than FDA-approved alternatives, though cost differentials varied widely (e.g., 72.8% higher for tirzepatide vs. 3,850% higher for PT-141 when comparing FDA-approved options). The authors concluded that consumer-directed third-party testing improves transparency but captures only a fraction of the full safety profile relevant to patients self-administering injectable compounds. Key limitations include reliance on a secondary dataset not collected under controlled research conditions and the inability to assess many other safety dimensions beyond purity and endotoxin levels.
Unknown journal · Apr 2026DOI ↗